Sign in to see private stats on your profile page — or add photo, interests, videos, mentoring, etc.

    Susanne Hildebrand-Zanki

    TitleSenior Project Analyst
    SchoolUCSF School of Medicine
    DepartmentMicrobiology and Immunology
    Address513 Parnassus Avenue
    San Francisco CA 94117
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview
      Susanne Hildebrand-Zanki is the UCSF Associate Vice Chancellor for Research. She has over twenty five-years of experience in senior-level management and operational positions in academia. Her extensive career with UC includes managing the Tobacco Related Disease Research Program at UCOP from 1990-2002. Upon coming to UCSF, Susanne has served as the associate director of administration of the Diabetes Center in 2003 and as the chief financial officer of the Immune Tolerance Network. Her expertise includes an in-depth knowledge of research administration, allocation, budget and management, program and policy development, leading effective teams, and process engineering and automation.

      Collapse ORNG Applications 
      Collapse In The News

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Kern DH, Shoemaker RH, Hildebrand-Zanki SU, Driscoll JS. Structure-activity relationships defining the cytotoxicity of catechol analogues against human malignant melanoma. Cancer Res. 1988 Sep 15; 48(18):5178-82. PMID: 3136917.
        View in: PubMed
      2. Kern DH, Morgan CR, Hildebrand-Zanki SU. In vitro pharmacodynamics of 1-beta-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum(II). Cancer Res. 1988 Jan 1; 48(1):117-21. PMID: 3334986.
        View in: PubMed
      3. Kern DH, Sondak VK, Morgan CR, Hildebrand-Zanki SU. Clinical application of the thymidine incorporation assay. Ann Clin Lab Sci. 1987 Nov-Dec; 17(6):383-8. PMID: 3688821.
        View in: PubMed
      4. Hildebrand-Zanki SU, Kern DH. In vitro assays for new drug screening: comparison of a thymidine incorporation assay with the human tumor colony-forming assay. Int J Cell Cloning. 1987 Sep; 5(5):421-31. PMID: 3624922.
        View in: PubMed
      5. Sondak VK, Hildebrand-Zanki SU, Butler A, Kern DH. Growth inhibitory effect of sodium azide in chemosensitivity assays. Int J Cell Cloning. 1987 May; 5(3):191-201. PMID: 2439615.
        View in: PubMed
      6. Hildebrand-Zanki SU, Kern DH. A rapid bioassay to determine stabilities of anticancer agents under conditions of the clonogenic assay. In Vitro Cell Dev Biol. 1986 May; 22(5):247-52. PMID: 3710996.
        View in: PubMed
      7. Kern DH, Drogemuller CR, Kennedy MC, Hildebrand-Zanki SU, Tanigawa N, Sondak VK. Development of a miniaturized, improved nucleic acid precursor incorporation assay for chemosensitivity testing of human solid tumors. Cancer Res. 1985 Nov; 45(11 Pt 1):5436-41. PMID: 4053017.
        View in: PubMed
      8. Sondak VK, Bertelsen CA, Tanigawa N, Hildebrand-Zanki SU, Morton DL, Korn EL, Kern DH. Clinical correlations with chemosensitivities measured in a rapid thymidine incorporation assay. Cancer Res. 1984 Apr; 44(4):1725-8. PMID: 6704978.
        View in: PubMed
      9. Storm FK, Roe DJ, Hildebrand-Zanki S, Worth GD, Morton DL, Kern DH. Natural thermal resistance of human tumor cells and the role of prostaglandin. Surgery. 1983 Aug; 94(2):376-83. PMID: 6576490.
        View in: PubMed
      Susanne's Networks
      Related Concepts
      Derived automatically from this person's publications.
      Related Authors
      People who share related concepts with this person.
      Back to TOP